Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Randomized Multicenter Study Comparing Horse Antithymocyte Globuline (hATG) + Cyclosporine A (CsA) With or Without Eltrombopag as Front-line Therapy for Severe Aplastic Anemia Patients.

NCT02099747 is registered in ClinicalTrials.gov with European Society for Blood and Marrow Transplantation as lead sponsor.

NCT NCT02099747
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02099747 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Randomized Multicenter Study Comparing Horse Antithymocyte Globuline (hATG) + Cyclosporine A (CsA) With or Without Eltrombopag as Front-line Therapy for Severe Aplastic Anemia Patients.
Lead sponsor
European Society for Blood and Marrow Transplantation
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2015
Completion date
December 31, 2020
Enrollment
202 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

severe aplastic anemia